T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cervical Cancer, Cervical Cancer, Cervical Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Women's Studies, Women's Studies |
| Therapuetic Areas: | Oncology, Reproductive |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 7/2/2016 |
| Start Date: | October 2014 |
| End Date: | June 2016 |
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers
Background:
The NCI Surgery Branch has developed an experimental therapy for treating patients with
cancer that involves taking white blood cells from the patient, growing them in the
laboratory in large numbers, genetically modifying these specific cells with a type of virus
(retrovirus) to attack only the tumor cells, and then giving the cells back to the patient.
This type of therapy is called gene transfer. Researchers want to test this on human
papilloma virus (HPV)-associated cancers.
Objective:
- The purpose of this study is to determine a safe number of these cells to infuse and to
see if these particular tumor-fighting cells (Anti-HPV E6) can shrink tumors associated with
HPV and test the toxicity of this treatment.
Eligibility:
- Adults age 18-66 with an HPV-16-associated cancer.
Design:
- Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and
undergo a history and physical examination, scans, x-rays, lab tests, and other tests
as needed
- Leukapheresis: If the patients meet all of the requirements for the study they will
undergo leukapheresis to obtain white blood cells to make the anti HPV E6 cells.
{Leukapheresis is a common procedure, which removes only the white blood cells from the
patient.}
- Treatment: Once their cells have grown, the patients will be admitted to the hospital
for the conditioning chemotherapy, the anti HPV E6 cells and aldesleukin. They will
stay in the hospital for about 4 weeks for the treatment.
Follow up: Patients will return to the clinic for a physical exam, review of side effects,
lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1
year as long as their tumors are shrinking. Follow up visits take up to 2 days.
The NCI Surgery Branch has developed an experimental therapy for treating patients with
cancer that involves taking white blood cells from the patient, growing them in the
laboratory in large numbers, genetically modifying these specific cells with a type of virus
(retrovirus) to attack only the tumor cells, and then giving the cells back to the patient.
This type of therapy is called gene transfer. Researchers want to test this on human
papilloma virus (HPV)-associated cancers.
Objective:
- The purpose of this study is to determine a safe number of these cells to infuse and to
see if these particular tumor-fighting cells (Anti-HPV E6) can shrink tumors associated with
HPV and test the toxicity of this treatment.
Eligibility:
- Adults age 18-66 with an HPV-16-associated cancer.
Design:
- Work up stage: Patients will be seen as an outpatient at the NIH clinical Center and
undergo a history and physical examination, scans, x-rays, lab tests, and other tests
as needed
- Leukapheresis: If the patients meet all of the requirements for the study they will
undergo leukapheresis to obtain white blood cells to make the anti HPV E6 cells.
{Leukapheresis is a common procedure, which removes only the white blood cells from the
patient.}
- Treatment: Once their cells have grown, the patients will be admitted to the hospital
for the conditioning chemotherapy, the anti HPV E6 cells and aldesleukin. They will
stay in the hospital for about 4 weeks for the treatment.
Follow up: Patients will return to the clinic for a physical exam, review of side effects,
lab tests, and scans about every 1-3 months for the first year, and then every 6 months to 1
year as long as their tumors are shrinking. Follow up visits take up to 2 days.
BACKGROUND:
- Metastatic or refractory/recurrent human papillomavirus (HPV)-16+ cancers (cervical,
vulvar, vaginal, penile, anal, and oropharyngeal cancers) are incurable and poorly
palliated by standard therapies.
- HPV-16+ cancers constitutively express the HPV-16 E6 oncoprotein, which is absent from
healthy human tissues.
- Administration of T cell receptor (TCR) gene engineered T cells can induce objective
tumor responses in certain malignancies.
- T cells genetically engineered with a TCR targeting HPV-16 E6 (E6 TCR) display specific
reactivity against HLA-A2+, HPV-16+ target cells.
OBJECTIVES:
Primary Objective
- To determine a safe dose of administration of autologous T cells transduced with an
anti-HPV-16 E6 TCR and aldesleukin to patients following a nonmyeloablative but
lymphodepleting preparative regimen.
- To determine the objective tumor response rate (Complete or Partial Response) and
duration in patients with metastatic or recurrent/refractory HPV-16+ cancers treated
with this regimen.
Secondary Objective(s)
- To determine the toxicity of this treatment regimen.
- To study immunologic correlates associated with E6 TCR gene therapy for HPV16+ cancers.
ELIGIBILITY:
- Patients greater than or equal to 18 years old and less than or equal to 70 years old
with metastatic or refractory/recurrent HPV-16+ cancer.
- Prior first line systemic therapy is required unless the patient declines standard
treatment.
- Patients must be HLA-A 02:01-positive.
DESIGN:
- Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen of
cyclophosphamide and fludarabine
- On day 0 patients will receive transduced lymphocytes and then begin high dose
aldesleukin
- The study will begin with a phase I dose escalation. After the MTD cell dose has been
determined, the patients will be enrolled into the phase II portion of the study.
- Clinical and immunologic response will be evaluated about 4 to 6 weeks after treatment
and then about every 1-6 months until disease progression
- Following a dose escalation phase of 9 to 18 patients, initially 21 evaluable patients
will be enrolled in the phase II portion of the study. If 0 to 1 of the 21 patients
experiences a clinical response, then no further patients will be enrolled. If 2 or
more of the first 21 evaluable patients enrolled have a clinical response, then accrual
will continue until a total of 41 evaluable patients have been enrolled. The accrual
ceiling will be set at 61 patients. Provided that about 1 patient every 6 weeks will be
enrolled onto this trial, approximately 4 years may be needed to accrue the maximum
number of patients.
- Metastatic or refractory/recurrent human papillomavirus (HPV)-16+ cancers (cervical,
vulvar, vaginal, penile, anal, and oropharyngeal cancers) are incurable and poorly
palliated by standard therapies.
- HPV-16+ cancers constitutively express the HPV-16 E6 oncoprotein, which is absent from
healthy human tissues.
- Administration of T cell receptor (TCR) gene engineered T cells can induce objective
tumor responses in certain malignancies.
- T cells genetically engineered with a TCR targeting HPV-16 E6 (E6 TCR) display specific
reactivity against HLA-A2+, HPV-16+ target cells.
OBJECTIVES:
Primary Objective
- To determine a safe dose of administration of autologous T cells transduced with an
anti-HPV-16 E6 TCR and aldesleukin to patients following a nonmyeloablative but
lymphodepleting preparative regimen.
- To determine the objective tumor response rate (Complete or Partial Response) and
duration in patients with metastatic or recurrent/refractory HPV-16+ cancers treated
with this regimen.
Secondary Objective(s)
- To determine the toxicity of this treatment regimen.
- To study immunologic correlates associated with E6 TCR gene therapy for HPV16+ cancers.
ELIGIBILITY:
- Patients greater than or equal to 18 years old and less than or equal to 70 years old
with metastatic or refractory/recurrent HPV-16+ cancer.
- Prior first line systemic therapy is required unless the patient declines standard
treatment.
- Patients must be HLA-A 02:01-positive.
DESIGN:
- Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen of
cyclophosphamide and fludarabine
- On day 0 patients will receive transduced lymphocytes and then begin high dose
aldesleukin
- The study will begin with a phase I dose escalation. After the MTD cell dose has been
determined, the patients will be enrolled into the phase II portion of the study.
- Clinical and immunologic response will be evaluated about 4 to 6 weeks after treatment
and then about every 1-6 months until disease progression
- Following a dose escalation phase of 9 to 18 patients, initially 21 evaluable patients
will be enrolled in the phase II portion of the study. If 0 to 1 of the 21 patients
experiences a clinical response, then no further patients will be enrolled. If 2 or
more of the first 21 evaluable patients enrolled have a clinical response, then accrual
will continue until a total of 41 evaluable patients have been enrolled. The accrual
ceiling will be set at 61 patients. Provided that about 1 patient every 6 weeks will be
enrolled onto this trial, approximately 4 years may be needed to accrue the maximum
number of patients.
-INCLUSION CRITERIA
1. Measurable metastatic or refractory/recurrent HPV-16+ cancer (determined by in situ
hybridization (ISH) or a polymerase chain reaction (PCR)-based test).
2. Patients must be HLA-A 02:01-positive.
3. All patients must have received prior first line standard therapy or declined
standard therapy, and have been either non-responders (progressive disease) or have
recurred.
4. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
asymptomatic are eligible. Lesions that have been treated with stereotactic
radiosurgery must be clinically stable for 1 month after treatment for the patient to
be eligible. Patients with surgically resected brain metastases are eligible.
5. Greater than or equal to 18 years of age and less than or equal to 70 years of age.
6. Able to understand and sign the Informed Consent Document.
7. Willing to sign durable power of attorney
8. Clinical performance status of ECOG 0 or 1.
9. Life expectancy of greater than 3 months.
10. Patients of both genders must be willing to practice birth control from the time of
enrollment on this study up to 4 months after treatment. Patients must be willing to
undergo testing for HPV-16 prior to becoming pregnant.
11. Women of child bearing potential must have a negative pregnancy test because of the
potentially dangerous effects of the treatment on the fetus.
12. Serology:
- Seronegative for HIV antibody. (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who are HIV
seropositive can have decreased immune-competence and thus are less responsive
to the experimental treatment and more susceptible to its toxicities.)
- Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
If hepatitis C antibody test is positive, then the patient must be tested for
the presence of antigen by RT-PCR and be HCV RNA negative.
13. Hematology:
- Absolute neutrophil count greater than 1000/mm3 without the support of
filgrastim.
- WBC greater than or equal to 3000/mm3
- Platelet count greater than or equal 100,000/mm3
- Hemoglobin greater than 8.0 g/dL
14. Chemistry:
- Serum ALT/AST less than or equal to 2.5 times the upper limit of normal
- Serum creatinine less than or equal to 1.6 mg/dL
- Total bilirubin less than or equal to to 1.5 mg/dL, except in patients with
Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dL
15. More than 4 weeks must have elapsed since any prior systemic therapy at the time the
patient receives the preparative regimen.
EXCLUSION CRITERIA:
1. Women of childbearing potential who are pregnant or breastfeeding. There are
potentially dangerous side effects of the treatment on the fetus or infant.
2. Active systemic infections (for e.g.: requiring anti-infective treatment),
coagulation disorders or other active major medical illnesses of the cardiovascular,
respiratory or immune system, as evidenced by a positive stress thallium or
comparable test, myocardial infarction, cardiac arrhythmias, obstructive or
restrictive pulmonary disease.
3. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease).
4. Concurrent opportunistic infections (The experimental treatment being evaluated in
this protocol depends on an intact immune system. Patients who have decreased immune
competence may be less responsive to the experimental treatment and more susceptible
to its toxicities).
5. Concurrent systemic steroid therapy.
6. History of severe immediate hypersensitivity reaction to cyclophosphamide or
fludarabine.
7. History of coronary revascularization or ischemic symptoms.
8. Documented LVEF of less than or equal to 45% tested. The following patients will
undergo cardiac evaluations
a. clinically significant atrial and/or ventricular arrhythmias including but not limited
to: atrial fibrillation, ventricular tachycardia, second or third degree heart block or
b. age greater than or equal 60 years old
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 866-820-4505
Click here to add this to my saved trials
